HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6-bromoindirubin-3'-oxime

structure in first source

Also Known As:

6BIO cpd

Networked: 21 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 6-bromoindirubin-3'-oxime: 21
Organic Chemicals: 133
- Amines: 4871
  - Hydroxylamines: 16
    - Oximes: 1292
      - 6-bromoindirubin-3'-oxime: 21

Experts

1.	Skaltsounis, Alexios-Leandros: 2 articles (10/2020 - 05/2014)
2.	Vougogiannopoulou, Konstantina: 2 articles (10/2020 - 05/2014)
3.	Li, Jimei: 2 articles (04/2017 - 01/2017)
4.	Wei, Ling: 2 articles (04/2017 - 01/2017)
5.	Yu, Shan Ping: 2 articles (04/2017 - 01/2017)
6.	Magiatis, Prokopios: 2 articles (08/2012 - 06/2011)
7.	Cui, Yating: 1 article (11/2021)
8.	Ge, Shaohua: 1 article (11/2021)
9.	Lin, Meng: 1 article (11/2021)
10.	Shang, Lingling: 1 article (11/2021)

Related Diseases

1.	Hematologic Neoplasms (Hematological Malignancy) 12/01/2019 - "The pharmacological modulators of GSK-3 such as ABT-869, 6-Bromoindirubin-3'-oxime (BIO), GS-87 and LY2090314 have shown promise in the treatment of hematological malignancy. "
2.	Mastitis 12/01/2019 - "We investigated the efficacy of the traditional herbal extract 6-bromoindirubin-3'-oxime (BIO) against lipopolysaccharide (LPS)-induced mastitis in mice and inflammatory signaling in mouse mammary epithelial cells (MMECs). "
3.	Melanoma (Melanoma, Malignant) 06/01/2011 - "In this study, we investigated the role of JAK/STAT3 signaling in 6-bromoindirubin-3'-oxime (6BIO)-mediated growth inhibition of human melanoma cells and assessed 6BIO as a potential anticancer drug candidate. " 06/01/2011 - "6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells." 08/01/2015 - "In this study, 6-bromoindirubin-3'-oxime (BIO), a serine/threonine kinase inhibitor with reported specificity for glycogen synthase kinase-3 beta (GSK-3β) inhibition, was evaluated in vitro in three canine melanoma cell lines (CML-10C2, UCDK9M2, and UCDK9M3) for β-catenin-mediated transcriptional activity, Axin2 gene and protein expression levels, cell proliferation, chemotoxicity, migration and invasion assays. "
4.	Inflammation (Inflammations) 06/21/2019 - "The present study was undertaken to examine the effects of 6-bromoindirubin-3'-oxime (BIO), a specific inhibitor of GSK-3β, on inflammation in ICH rats. " 12/01/2019 - "6-Bromoindirubin-3'-Oxime Suppresses LPS-Induced Inflammation via Inhibition of the TLR4/NF-κB and TLR4/MAPK Signaling Pathways." 10/01/2012 - "TPA/IFN-γ induced GSK-3 activation, which in turn activated signal transducer and activator of transcription 1. Inhibiting GSK-3 pharmacologically, by administering 6-bromoindirubin-3'-oxime (1.5 μg per ear), and genetically, with lentiviral-based short-hairpin RNA, reduced TPA-induced acute skin inflammation but not T-cell infiltration. "
5.	Parkinson Disease (Parkinson's Disease) 01/01/2018 - "In the present study, we investigated the effects of 6-bromoindirubin-3'-oxime (BIO) on dopaminergic differentiation of human immortalized RenVm cells in order to obtain a set of fully differentiated cells for transplantation in Parkinson's disease. "

Related Drugs and Biologics

1.	Glycogen Synthase Kinase 3
2.	Lipopolysaccharides
3.	3- (9- fluoro- 2- (piperidin- 1- ylcarbonyl)- 1,2,3,4- tetrahydro(1,4)diazepino(6,7,1- hi)indol- 7- yl)- 4- imidazo(1,2- a)pyridin- 3- yl- 1H- pyrrole- 2,5- dione
4.	linifanib
5.	Glycogen Synthase (Synthase I)
6.	Catenins
7.	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)
8.	Proteins (Proteins, Gene)
9.	7-bromoindirubin-3'-oxime
10.	Glycogen Synthase Kinases

Related Therapies and Procedures

1.	Transplantation
2.	Drug Therapy (Chemotherapy)
3.	Treatment Delay